Non-Melanoma Skin Cancer and Other Epidermal Skin Tumours

Rook's Textbook of Dermatology: Eighth Edition

Volumn 3, Issue , 2010, Pages 2568-2615

  Quinn, Anthony G ^a   Perkins, William ^b  

^a Synageva BioPharma Corporation   (United States)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Benign epidermal tumours seborrhoeic keratosis; Bowen's disease intraepidermal SCC characterized by persistent, non elevated, red, scaly or crusted plaque; Cancer as a genetic disease; Complexity of cellular composition of skin range of tumours arising within it being wide; Human papillomaviruses; Immunological effects of ultraviolet radiation; Muir Torre syndrome autosomal dominant syndrome, one or more sebaceous neoplasms; Non melanoma skin cancer (NMSC), most common human cancer; Non melanoma skin cancer and other epidermal skin tumours; Non melanoma skin cancer and related premalignant lesions

Indexed keywords

EID: 84888655765     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444317633.ch52     Document Type: Chapter

References (491)

1. Giles GG, Marks R, Foley P. The incidence of non-melanocytic skin cancer in Australia. BMJ 1988; 296: 13-7.
2. Marks R, Staples M, Giles G. Trends in non-melanocytic skin cancer treated in Australia: the second national survey. Int J Cancer 1993; 53: 585-90.
3. Chuang TY, Popescu NA, Su D et al. Squamous cell carcinoma: a populationbased incidence study in Rochester, Minnesota. Arch Dermatol 1990; 126: 185-8.
4. Miller DL, Weinstock MA. Non-melanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994; 30: 774-8.
5. Weinstock MA, Bogars HA, Ashley M et al. Non-melanoma skin cancer mortality. Arch Dermatol 1991; 127: 1194-7.
6. Gloster HM Jr, Brodland DG. The epidemiology of skin cancer. Dermatol Surg 1996; 22: 217-26.
7. Holme SA, Malinovszky K, Roberts DL. Changing trends in non-melanoma skin cancer in South Wales, 1988-98. Br J Dermatol 2000; 143: 1224-9.
8. Dahl E, Aberg M, Rausing A, Rausing EL. Basal cell carcinoma: an epidemiologic study in a defined population. Cancer 1992; 70: 104-8.
9. Vitasa BC, Taylor HR, Strickland PT et al. Association of non-melanoma skin cancer and actinic keratosis with cumulative solar ultraviolet exposure in Maryland watermen. Cancer 1990; 65: 2811-7.
10. Hyde JN. On the influence of light in the production of cancer of the skin. Am J Med Sci 1906; 131: 1-22.
11. Dubreuilh W. Epitheliomatose d'origine solaire. Ann Dermatol Syphilol 1907; 45: 387-416.
12. Fears TR, Scotto J. Estimating increases in skin cancer morbidity due to increases in ultraviolet radiation exposure. Cancer Invest 1983; 1: 119-26.
13. Luande J, Henschke CI, Mohammed N. The Tanzanian human albino skin: natural history. Cancer 1985; 55: 1823-8.
14. Roberts DL. Incidence of non-melanoma skin cancer in West Glamorgan, South Wales. Br J Dermatol 1990; 122: 399-403.
15. International Agency for Research on Cancer (IARC). Solar and ultra-violet radiation. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 55. Lyons: IARC, 1992.
16. Armstrong BK, Kricker A. Epidemiology of sun exposure and skin cancer. Cancer Surv 1996; 26: 133-53.
17. English DR, Armstrong BK. Melanocytic nevi in children. I. Anatomic sites and demographic and host factors. Am J Epidemiol 1994; 139: 390-401.
18. Kricker A, Armstrong BK, English DR, Heenan PJ. A dose-response curve for sun exposure and basal cell carcinoma. Int J Cancer 1995; 60: 482-8.
19. Rosso S, Zanetti R, Martinez C et al. The multicentre south European study 'Helios'. II. Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996; 73: 1447-54.
20. de Laat JM, de Gruijl FR. The role of UVA in the aetiology of non-melanoma skin cancer. Cancer Surv 1996; 26: 173-91.
21. Roest MA, Keane FM, Agnew K et al. Multiple squamous skin carcinomas following excess sunbed use. J R Soc Med 2001; 94: 636-7.
22. Speight EL, Dahl MG, Farr PM. Actinic keratosis induced by use of sunbed. BMJ 1994; 308 (6925): 415.
23. Diffey BL, Farr PM. The challenge of follow-up in narrowband ultraviolet B phototherapy. Br J Dermatol 2007; 157: 344-9.
24. Pasker-de Jong PC, Wielink G, van der Valk PG, van der Wilt GJ. Treatment with UV-B for psoriasis and non-melanoma skin cancer: a systematic review of the literature. Arch Dermatol 1999; 135: 834-40.
25. Stern RS, Thibodeau LA, Kleinerman RA et al. Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. N Engl J Med 1979; 300: 809-13.
26. Henseler T, Christophers E, Honigsmann H, Wolff K. Skin tumors in the European PUVA Study. Eight-year follow-up of 1643 patients treated with PUVA for psoriasis. J Am Acad Dermatol 1987; 16: 108-16.
27. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA): a meta-analysis. Arch Dermatol 1998; 134: 1582-5.
28. Lim JL, Stern RS. High levels of ultraviolet B exposure increase the risk of nonmelanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol 2005; 124: 505-13.
29. Lever LR, Farr PM. Skin cancers or premalignant lesions occur in half of high-dose PUVA patients. Br J Dermatol 1994; 131: 215-9.
30. Potter M. Percival Potts' Contribution to Cancer Research. National Cancer Institute. Monograph 10. Washington DC: Washington Government, 1974: 1-19.
31. Hueper WC. Chemically Induced Skin Cancers in Man. Monograph 10. Washington DC: National Cancer Institute, 1963: 377-91.
32. Waterhouse JAH. Cutting oils and cancer. Ann Occup Hyg 1971; 14: 161-70.
33. Neubauer O. Arsenical cancer: a review. Br J Cancer 1947; 1: 192-251.
34. Prasad HR, Malhotra AK, Hanna N et al. Arsenicosis from homeopathic medicines: a growing concern. Clin Exp Dermatol 2006; 31: 497-8.
35. Tseng WP, Chu HM, How SW et al. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst 1968; 40: 453-63.
36. Zhang A, Feng H, Yang G et al. Unventilated indoor coal-fired stoves in Guizhou province, China: cellular and genetic damage in villagers exposed to arsenic in food and air. Environ Health Perspect 2007; 115: 653-8.
37. Meara RH. Epitheliomata after radiotherapy of the spine. Br J Dermatol 1968; 80: 620.
38. Shore RE, Albert RE, Reed M et al. Skin cancer incidence among children irradiated for ringworm of the scalp. Radiat Res 1984; 100: 192-204.
39. Perkins JL, Liu Y, Mitby PA et al. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. J Clin Oncol 2005; 23: 3733-41.
40. Evans DG, Farndon PA, Burnell LD et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 1991; 64: 959-61.
41. Zvulunov A, Strother D, Zirbel G et al. Nevoid basal cell carcinoma syndrome: report of a case with associated Hodgkin's disease. J Pediatr Hematol Oncol 1995; 17: 66-70.
42. Aziz SA, Hussain KS, Ahmad KN et al. Profile of Kangari cancer: a prospective study. Burns 1998; 24: 763-6.
43. Rudolph CM, Soyer HP, Wolf P, Kerl H. Squamous epithelial carcinoma in erythema ab igne. Hautarzt 2000; 51: 260.
44. Akasaka T, Kon S. Two cases of squamous cell carcinoma arising from erythema ab igne. Nippon Hifuka Gakkai Zasshi 1989; 99: 735-74.
45. zur Hausen HH. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-50.
46. McGrae JD Jr, Greer CE, Manos MM. Multiple Bowen's disease of the fingers associated with human papilloma virus type 16. Int J Dermatol 1993; 32: 104-7.
47. Hara H, Honda A, Suzuki H et al. Detection of human papillomavirus type 58 in polydactylous Bowen's disease on the fingers and toes of a woman-concurrent occurrence of invasive vulval and cervical carcinomas. Dermatology 2004; 209: 218-22.
48. Majewski S, Jablonska S. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol 1995; 131: 1312-8.
49. Bouwes Bavinck JN, Euvrard S, Naldi L et al. Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a casecontrol study in The Netherlands, United Kingdom, Germany, France, and Italy. J Invest Dermatol 2007; 127: 1647-56.
50. Harwood CA, Surentheran T, McGregor JM et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000; 61: 289-97.
51. Harwood CA, Surentheran T, Sasieni P et al. Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin. Br J Dermatol 2004; 150: 949-57.
52. Gorlin RJ, Vickers RA, Kelln E et al. The multiple basal-cell naevi syndrome: analysis of a syndrome consisting of multiple naevoid basal-cell carcinoma, jaw cysts, skeletal anomalies, medulloblastoma, and hyporesponsiveness to parathormone. Cancer 1965; 18: 89-104.
53. Gorlin RJ. The naevoid basal cell carcinoma syndrome. Medicine 1987; 66: 98-113.
54. Evans DG, Ladusans EJ, Rimmer S et al. Complications of the naevoid basal cell carcinoma syndrome: results of a population-based study. J Med Genet 1993; 30: 460-4.
55. Quinn AG. Molecular genetics of human non-melanoma skin cancer. Cancer Surv 1996; 26: 89-114.
56. Johnson RL, Rothman AL, Xie J et al. Human homolog of patched, a candidate gene for the basal cell naevus syndrome. Science 1996; 272: 1668-71.
57. Bale AE, Gailani MR, Leffell DJ. The Gorlin syndrome gene: a tumor suppressor active in basal cell carcinogenesis and embryonic development. Proc Assoc Am Physicians 1995; 107: 253-7.
58. Soufir N, Gerard B, Portela M et al. PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study. Br J Cancer 2006; 95: 548-53.
59. Nowakowska B, Kutkowska-Kazmierczak A, Stankiewicz P et al. A girl with deletion 9q22.1-q22.32 including the PTCH and ROR2 genes identified by genome-wide array-CGH. Am J Med Genet A 2007; 143: 1885-9.
60. Olivieri C, Maraschio P, Caselli D et al. Interstitial deletion of chromosome 9, int del(9)(9q22.31-q31.2), including the genes causing multiple basal cell nevus syndrome and Robinow/brachydactyly 1 syndrome. Eur J Pediatr 2003; 162: 100-3.
61. Howell JB. Naevoid basal cell carcinoma syndrome: profile of genetic and environmental features in oncogenesis. J Am Acad Dermatol 1984; 11: 98-104.
62. Kimonis VE, Goldstein AM, Pastakia B et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997; 69: 299-308.
63. Southwick GJ, Schwartz RA. The basal cell naevus syndrome: disasters occurring among a series of 36 patients. Cancer 1979; 44: 2294-305.
64. Wilson LC, Ajayi-Obe E, Bernhard B et al. Patched mutations and hairy skin patches: a new sign in Gorlin syndrome. Am J Med Genet A 2006; 140: 2625-30.
65. Binkley GW, Johnson HH. Epithelioma adenoides cysticum: basal cell naevi, agenesis of the corpus callosum and dental cysts. Arch Dermatol 1951; 63: 73-84.
66. Anderson DE, Taylor WB, Falls MF et al. The naevoid basal cell carcinoma syndrome. Am J Hum Genet 1967; 19: 12-22.
67. Berlin NI, van Scott EJ, Clendenning WE et al. Basal cell naevus syndrome: combined clinical staff conference at the National Institute of Health. Ann Intern Med 1966; 64: 403-21.
68. Clendenning WE, Block JB, Radde IC. Basal cell naevus syndrome. Arch Dermatol 1964; 90: 38-53.
69. Gorlin RJ, Goltz RW. Multiple naevoid basal-cell epithelioma, jaw cysts and bifid rib: a syndrome. N Engl J Med 1960; 262: 908-12.
70. Gorlin RJ, Yunis JJ, Tuna N. Multiple naevoid basal cell carcinoma, odontogenic keratocysts and skeletal anomalies: a syndrome. Acta Derm Venereol (Stockh) 1963; 43: 39-55.
71. Howell JB, Caro MR. The basal-cell naevus: its relationship to multiple cutaneous cancers and associated anomalies of development. AMA Arch Dermatol 1959; 79: 67-80.
72. Van Dijk E, Sanderink JFH. Basal cell naevus syndrome. Dermatologica 1967; 134: 101-6.
73. Evans DG, Farndon PA, Burnell LD et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 1991; 64: 959-61.
74. Zackheim HS, Howell JB, Loud AV. Naevoid basal cell carcinoma syndrome: some histologic observations on the cutaneous lesions. Arch Dermatol 1966; 93: 317-23.
75. Howell JB, Mehregan AH. Pursuit of the pits in the naevoid basal cell carcinoma syndrome. Arch Dermatol 1970; 102: 586-97.
76. Holubar K, Matras H, Smalik AV. Multiple palmar basal cell epitheliomas in basal cell naevus syndrome. Arch Dermatol 1970; 10: 679-82.
77. Howell JB, Freeman RG. Structure and significance of the pits and their tumours in the naevoid basal cell carcinoma syndrome. J Am Acad Dermatol 1980; 2: 224-38.
78. Mason JK, Helwig EB, Graham JH. Pathology of the naevoid basal cell carcinoma syndrome. Arch Pathol 1965; 79: 401-8.
79. Goette DK. Topical chemotherapy with 5-fluorouracil: a review. J Am Acad Dermatol 1981; 4: 633-49.
80. Micali G, De Pasquale R, Caltabiano R et al. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell naevus syndrome: a preliminary report. J Dermatolog Treat 2002; 13: 123-7.
81. Goldberg LH, Rubin HA. Management of basal cell carcinoma: which option is best? Postgrad Med 1989; 85: 57-8, 61-3.
82. Cristofolini M, Zumiani G, Scappini P, Piscioli F. Aromatic retinoid in the chemoprevention of the progression of naevoid basal-cell carcinoma syndrome. J Dermatol Surg Oncol 1984; 10: 778-81.
83. Plosila M, Kiistala R, Niemi K-M. The Bazex syndrome: follicular atrophoderma with multiple basal cell carcinomas, hypotrichosis and hypohidrosis. Clin Exp Dermatol 1981; 6: 31-41.
84. Bazex A, Dupré A, Christol B. Atrophodermie folliculaire proliférations basocellulaires et hypotrichose. Ann Dermatol Syphiligr 1966; 93: 241-54.
85. Viksnin SP, Berlin A. Follicular atrophoderma and basal cell carcinomas. Arch Dermatol 1977; 113: 948-51.
86. Vabres P, Lacombe D, Rabinowitz LG et al. The gene for Bazex-Dupré-Christol syndrome maps to chromosome Xq. J Invest Dermatol 1995; 105: 87-91.
87. Markey AC, Lane EB, Macdonald DM, Leigh IM. Keratin expression in basal cell carcinomas. Br J Dermatol 1992; 126: 154-60.
88. Michaelsson G, Olsson E, Westermark P. The Rombo syndrome: a familial disorder with vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, basal cell carcinomas and peripheral vasodilation with cyanosis. Acta Derm Venereol 1981; 61: 497-503.
89. van Steensel MA, Jaspers NG, Steijlen PM. A case of Rombo syndrome. Br J Dermatol 2001; 144: 1215-81.
90. Charteris AA. Self-healing epithelioma of the skin. Am J Roentgenol 1951; 65: 459-64.
91. Currie AR, Smith JF. Multiple primary spontaneous-healing squamous-cell carcinomata of the skin. J Pathol Bacteriol 1952; 64: 827-39.
92. Ferguson-Smith MA, Wallace D, James Z et al. Multiple self-healing epitheliomata. Birth Defects 1971; 7: 157-63.
93. D'Alessandro M, Coats SE, Morley SM et al. Multiple self-healing squamous epithelioma in different ethnic groups: more than a founder mutation disorder? J Invest Dermatol 2007; 127: 2336-44.
94. Bose S, Morgan LJ, Booth DR et al. The elusive multiple self-healing squamous epithelioma (MSSE) gene: further mapping, analysis of candidates, and loss of heterozygosity. Oncogene 2006; 25: 806-12.
95. Witten VH, Zak FG. Multiple, primary, self-healing prickle-cell epithelioma of the skin. Cancer 1952; 5: 539-50.
96. Rook A, Moffatt JL. Multiple self-healing epithelioma of Ferguson-Smith type: report of a case of unilateral distribution. Arch Dermatol 1956; 74: 525-32.
97. Stary A, Sarasin A. The genetic basis of xeroderma pigmentosum and trichothiodystrophy syndromes. Cancer Surv 1996; 26: 155-71.
98. Cleaver JE. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Cancer 2005; 5: 564-73.
99. Jones B, Oh C, Mangold E et al. Muir-Torre syndrome: diagnostic and screening guidelines. Australas J Dermatol 2006; 47: 266-9.
100. Ponti G, Losi L, Pedroni M et al. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. J Invest Dermatol 2006; 126: 2302-7.
101. Arnold A, Payne S, Fisher S et al. An individual with Muir-Torre syndrome found to have a pathogenic MSH6 gene mutation. Fam Cancer 2007; 6: 317-21.
102. Honchel R, Halling KC, Schaid DJ et al. Microsatellite instability in Muir-Torre syndrome. Cancer Res 1994; 54: 1159-63.
103. Quinn AG, Healy E, Rehman I et al. Microsatellite instability in human nonmelanoma and melanoma skin cancer. J Invest Dermatol 1995; 104: 309-12.
104. Swale VJ, Quinn AG, Wheeler JM et al. Microsatellite instability in benign skin lesions in hereditary non-polyposis colorectal cancer syndrome. J Invest Dermatol 1999; 113: 901-5.
105. Harwood CA, Swale VJ, Bataille VA et al. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. J Invest Dermatol 2001; 116: 246-53.
106. Levi Z, Hazazi R, Kedar-Barnes I et al. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. Am J Transplant 2007; 7: 476-9.
107. Eads CA, Nickel AE, Laird PW. Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc (Min/) Dnmt1-hypomorphic mice. Cancer Res 2002; 62: 1296-9.
108. MacPhee M, Chepenik KP, Liddell RA et al. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 1995; 81: 957-66.
109. Armstrong BK, Kricker A. Epidemiology of sun exposure and skin cancer. Cancer Surv 1996; 26: 133-53.
110. Lear JT, Smith AG, Strange RC, Fryer AA. Detoxifying enzyme genotypes and susceptibility to cutaneous malignancy. Br J Dermatol 2000; 142: 8-15.
111. Kang SY, Lee KG, Lee W et al. Polymorphisms in the DNA repair gene XRCC1 associated with basal cell carcinoma and squamous cell carcinoma of the skin in a Korean population. Cancer Sci 2007; 98: 716-20.
112. McCarty KM, Ryan L, Houseman EA et al. A case-control study of GST polymorphisms and arsenic related skin lesions. Environ Health 2007; 6: 5.
113. Edwards MJ, Hirsch RM, Broadwater JR et al. Squamous cell carcinoma arising in previously burned or irradiated skin. Arch Surg 1989; 124: 115-7.
114. Ikegawa S, Saida T, Takizawa Y et al. Vimentin-positive squamous cell carcinoma arising in a burn scar: a highly malignant neoplasm composed of acantholytic round keratinocytes. Arch Dermatol 1989; 125: 1672-6.
115. Sulica VI, Kao GF. Squamous-cell carcinoma of the scalp arising in lesions of discoid lupus erythematosus. Am J Dermatopathol 1988; 10: 137-41.
116. Imtiaz KE, Khaleeli AA. Squamous cell carcinoma developing in necrobiosis lipoidica. Diabet Med 2001; 18: 325-8.
117. Beljaards RC, Groen J, Starink TM. Bilateral squamous cell carcinomas arising in long-standing necrobiosis lipoidica. Dermatologica 1990; 180: 96-8.
118. Newman C, Wagner RF Jr, Tyring SK, Spigel GT. Squamous cell carcinoma secondary to recessive dystrophic epidermolysis bullosa: a report of 4 patients with 17 primary cutaneous malignancies. J Dermatol Surg Oncol 1992; 18: 301-5.
119. Bosch RJ, Gallardo MA, Ruiz DP et al. Squamous cell carcinoma secondary to recessive dystrophic epidermolysis bullosa: report of eight tumours in four patients. J Eur Acad Dermatol Venereol 1999; 13: 198-204.
120. Arbiser JL, Fine JD, Murrell D et al. Basic fibroblast growth factor: a missing link between collagen VII, increased collagenase, and squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. Mol Med 1998; 4: 191-5.
121. McGregor JM, Proby CM. Skin cancer in transplant recipients. Lancet 1995; 346: 964-5.
122. Hartevelt MM, Bavinck JN, Kootte AM et al. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990; 49: 506-9.
123. Hardie IR, Strong RW, Hartley LC et al. Skin cancer in Caucasian renal allograft recipients living in a subtropical climate. Surgery 1980; 87: 177-83.
124. Bouwes Bavinck JN. Epidemiological aspects of immunosuppression: role of exposure to sunlight and human papillomavirus on the development of skin cancer. Hum Exp Toxicol 1995; 14: 98.
125. Bouwes Bavinck JN, Feltkarmp M, Struijk L, ter Scheggett J. Human papillomavirus infection and skin cancer risk in organ transplant recipients. J Invest Dermatol Symp Proc 2001; 6: 207-11.
126. Taylor AE, Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. Acta Derm Venereol 1992; 72: 115-9.
127. Quinn AG. Molecular genetics of human non-melanoma skin cancer. Cancer Surv 1996; 26: 89-114.
128. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-99.
129. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-74.
130. Jiricny J, Nystrom-Lahti M. Mismatch repair defects in cancer. Curr Opin Genet Dev 2000; 10: 157-61.
131. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-9.
132. Brash DE, Rudolph JA, Simon JA et al. A role for sunlight in skin cancer: UVinduced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991; 88: 10124-8.
133. Teh MT, Blaydon D, Chaplin T et al. Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res 2005; 65: 8597-603.
134. Purdie KJ, Lambert SR, Teh MT et al. Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis. Genes Chromosomes Cancer 2007; 46: 661-9.
135. Yuspa SH, Dlugosz AA, Denning MF, Glick AB. Multistage carcinogenesis in the skin. J Invest Dermatol Symp Proc 1996; 1: 147-50.
136. Burns PA, Bremner R, Balmain A. Genetic changes during mouse skin tumorigenesis. Environ Health Perspect 1991; 93: 41-4.
137. Jonason AS, Kunala S, Price GJ et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 1996; 93: 14025-9.
138. Nagase H, Mao JH, Balmain A. A subset of skin tumor modifier loci determines survival time of tumor-bearing mice. Proc Natl Acad Sci USA 1999; 96: 15032-7.
139. Peak MJ, Peak JG. Solar-ultraviolet-induced damage to DNA. Photodermatol 1989; 6: 1-15.
140. Ziegler A, Jonason AS, Leffell DJ et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773-6.
141. Peak MJ, Peak JG. DNA-to-protein crosslinks and backbone breaks caused by far-and near-ultraviolet, and visible light radiations in mammalian cells. Basic Life Sci 1986; 38: 193-202.
142. Applegate LA, Frenk E. Oxidative defense in cultured human skin fibroblasts and keratinocytes from sun-exposed and non-exposed skin. Photodermatol Photoimmunol Photomed 1995; 11: 95-101.
143. Mitchell DL, Jen J, Cleaver JE. Sequence specificity of cyclobutane pyrimidine dimers in DNA treated with solar (ultraviolet B) radiation. Nucl Acids Res 1992; 20: 225-9.
144. Ananthaswamy HN, Fourtanier A, Evans RL et al. p53 Mutations in hairless SKH-hr1 mouse skin tumors induced by a solar simulator. Photochem Photobiol 1998; 67: 227-32.
145. Gorelick NJ. Overview of mutation assays in transgenic mice for routine testing. Environ Mol Mutagen 1995; 25: 218-30.
146. Ley RD, Applegate LA, Freeman SE. Photorepair of ultraviolet radiation-induced pyrimidine dimers in corneal DNA. Mutat Res 1988; 194: 49-55.
147. Yarosh D, Klein J, Kibitel J et al. Enzyme therapy of xeroderma pigmentosum: safety and efficacy testing of T4N5 liposome lotion containing a prokaryotic DNA repair enzyme. Photodermatol Photoimmunol Photomed 1996; 12: 122-30.
148. Stary A, Sarasin A. The genetic basis of xeroderma pigmentosum and trichothiodystrophy syndromes. Cancer Surv 1996; 26: 155-71.
149. Eveno E, Bourre F, Quilliet X et al. Different removal of ultraviolet photoproducts in genetically related xeroderma pigmentosum and trichothiodystrophy diseases. Cancer Res 1995; 55: 4325-32.
150. Madzak C, Armier J, Stary A et al. UV-induced mutations in a shuttle vector replicated in repair deficient trichothiodystrophy cells differ with those in genetically-related cancer prone xeroderma pigmentosum. Carcinogenesis 1993; 14: 1255-60.
151. Kripke ML. Ultraviolet radiation and immunology: something new under the sun. Presidential address. Cancer Res 1994; 54: 6102-5.
152. Streilein JW. Immunogenetics of sunlight-induced skin cancer. Photochem Photobiol 1996; 63: 422-4.
153. Loser K, Apelt J, Voskort M et al. IL-10 controls ultraviolet-induced carcinogenesis in mice. J Immunol 2007; 179: 365-71.
154. Meeran SM, Mantena SK, Meleth S et al. Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas. Mol Cancer Ther 2006; 5: 825-32.
155. Yoshikawa T, Rae V, Bruins-Slot W et al. Susceptibility to effects of UVB radiation on induction of contact hypersensitivity as a risk factor for skin cancer in humans. J Invest Dermatol 1990; 9: 530-6.
156. Cooper KD, Oberhelman L, Hamilton TA et al. UV exposure reduces immunization rates and promotes tolerance to epicutaneous antigens in humans: relationship to dose, CD1a-DR epidermal macrophage induction, and Langerhans' cell depletion. Proc Natl Acad Sci USA 1992; 89: 8497-501.
157. Tie C, Golomb C, Taylor JR, Streilein JW. Suppressive and enhancing effects of ultraviolet B radiation on expression of contact hypersensitivity in man. J Invest Dermatol 1995; 104: 18-22.
158. Streilein JW, Taylor JR, Vincek V et al. Relationship between ultraviolet radiation-induced immunosuppression and carcinogenesis. J Invest Dermatol 1994; 103 (Suppl. 5): 107S-11S.
159. Zur-Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-50.
160. Kaur P, McDougall JK. Characterization of primary human keratinocytes transformed by human papillomavirus type 18. J Virol 1988; 62: 1917-24.
161. Rehman I, Quinn AG, Takata M et al. Low frequency of allelic loss in skin tumours from immunosuppressed individuals. Br J Cancer 1997; 76: 757-9.
162. Jackson S, Harwood C, Thomas M et al. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 2000; 14: 3065-73.
163. Storey A. Papillomaviruses: death-defying acts in skin cancer. Trends Mol Med 2002; 8: 417.
164. Graham G. Statistical data on malignant tumours in cryosurgery: 1982. J Dermatol Surg Oncol 1983; 9: 238-9.
165. Zacharian SA. Cryosurgery of cutaneous carcinomas. An 18 year study of 3022 patients with 4228 carcinomas. J Am Acad Dermatol 1983; 9: 947-56.
166. Kokoszka A, Scheinfeld N. Evidence based review of the use of cryosurgery in the treatment of basal cell carcinoma. Dermatol Surg 2003; 29: 566-71.
167. Jamarilo-Ayerbe F. Cryosurgery in difficult to treat basal cell carcinoma. Int J Dermatol 2000; 39: 223-9.
168. Johnson TM, Tromovitch TA, Swanson NA. Combined curettage and excision: a treatment method for primary basal cell carcinoma. J Am Acad Dermatol 1991; 24: 613-7.
169. Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008; 159: 1245-66.
170. Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology. J Am Acad Dermatol 2000; 42: 389-413.
171. Morton CA. The emerging role of 5-ALA-PDT in dermatology: is PDT superior to standard treatments? J Dermatolog Treat 2002; 13 (Suppl. 1): S25-9.
172. Haller JC, Cairnduff F, Slack G et al. Routine double treatments of superficial basal cell carcinomas using aminolaevulinic acid-based photodynamic therapy. Br J Dermatol 2000; 143: 1270-5.
173. Braathen LR, Szeimies R-M, Basset-Sequin N et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007; 56: 125-43.
174. National Institute for Health and Clinical Excellence. Photodynamic Therapy for Non-melanoma Skin Tumours (Including Premalignant and Primary Non-metastatic Skin Lesions), 2006. www.nice.org.uk/nicemedia/pdf/ip/IPG155publicinfo.pdf
175. Rhodes LE, de Rei MA, Leifsdottir R et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007; 143: 1131-6.
176. Caty V, Liu Y, Viau G, Bissonnette R. Multiple large surface photodynamic therapy sessions with topical methyl aminolaevulinate in PTCH heterozygous mice. Br J Dermatol 2006; 154: 740-2.
177. Nouri K, Chang A, Trent JT, Jimenez GP. Ultrapulse CO2 used for the successful treatment of basal cell carcinomas found in patients with basal cell naevus syndrome. Dermatol Surg 2002; 28: 287-90.
178. Mackenzie-Wood A, Kossard S, de Launey J et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001; 44: 462-70.
179. Abide JM, Nahai F, Bennett RG. The meaning of surgical margins. Plast Reconstr Surg 1984; 73: 492-7.
180. Lawrence CM. Mohs micrographic surgery for basal cell carcinoma. Clin Exp Dermatol 1999; 24: 130-3.
181. Shriner DL, McCoy DK, Goldberg DJ, Wagner RF Jr. Mohs micrographic surgery. J Am Acad Dermatol 1998; 39: 79-97.
182. Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35-48.
183. Motley RJ, Preston PW, Lawrence CM. Multiprofessional Guidelines for the Management of the Patient with Primary Cutaneous Squamous Cell Carcinoma. www.bad.org.uk.
184. Tromovitch TA. Skin cancer: treatment by curettage and electrodesiccation. Calif Med 1965; 103: 107-8.
185. Freeman RG, Knox JM, Heaton CL. The treatment of skin cancer: a statistical study of 1341 skin tumours comparing results obtained with irradiation, surgery and curettage followed by electrodesiccation. Cancer 1964; 17: 535-8.
186. Simmonds WL. Management of actinic keratoses with topical 5-fluorouracil. Cutis 1976; 18: 298-300.
187. Carter VH, Smith KW, Noojin RO. Xeroderma pigmentosum: treatment with topically applied fluorouracil. Arch Dermatol 1968; 98: 526-7.
188. Wright TI, Spencer JM, Flowers FP. Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol 2006; 54: 933-46.
189. Bath-Hextall FJ, Leonardi-Bee J, Somchand N et al. Interventions for Preventing Non-melanoma Skin Cancers in High-risk Groups. www.cochrane.org/reviews.
190. Moriarty M, Dunn J, Darragh A et al. Etretinate in treatment of actinic keratoses: a double-blind crossover study. Lancet 1982; 1: 364-5.
191. Miller SJ. Biology of basal cell carcinoma. I. J Am Acad Dermatol 1991; 24: 1-13.
192. Miller SJ. Biology of basal cell carcinoma. II. J Am Acad Dermatol 1991; 24: 161-75.
193. Pollack SV, Goslen JB, Sherertz EF et al. The biology of basal cell carcinoma: a review. J Am Acad Dermatol 1982; 7: 569-77.
194. Chuang TY, Popescu A, Su WPD et al. Basal cell carcinoma: a population-based incidence study. J Am Acad Dermatol 1990; 22: 413-7.
195. Marks R, Staples M, Giles GG. Trends in non-melanocytic skin cancer treated in Australia: the second national survey. Int J Cancer 1993; 53: 585-90.
196. Reizner GT, Chuang TY, Elpern DJ et al. Basal cell carcinoma in Kauai, Hawaii: the highest documented incidence in the United States. J Am Acad Dermatol 1993; 29: 184-9.
197. Hogan DJ, To T, Gran L et al. Risk factors for basal carcinoma. Int J Dermatol 1989; 28: 591-4.
198. Kricker A, Armstrong BK, English DR, Heenan PJ. A dose-response curve for sun exposure and basal cell carcinoma. Int J Cancer 1995; 60: 482-8.
199. Kricker A, Armstrong BK, English DR, Heenan PJ. Does intermittent sun exposure cause basal cell carcinoma? A case-control study in Western Australia. Int J Cancer 1995; 60: 489-94.
200. Rosso S, Zanetti R, Martinez C et al. The multicentre south European study 'Helios' II. Different sun exposure pattern in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996; 73: 1447-54.
201. Zanetti R, Rosso S, Martinez C et al. The multicentre European Helios study I. Skin characteristics and sunburns in basal and squamous cell carcinomas of the skin. Br J Cancer 1996; 73: 1440-6.
202. Suarez B, Lopez-Abente G, Martinez C et al. Occupation and skin cancer: the results of the HELIOS-I multicenter case-control study. BMC Public Health 2007; 7: 180.
203. Miki Y. Basal cell epithelioma among Japanese. Australas J Dermatol 1968; 9: 304-13.
204. Shanmugaranam K, Labrooy EB. Skin Cancer in Singapore. Monograph 10. Washington DC: National Cancer Institute, 1963: 127-40.
205. Weimar VW, Ceilley RI, Goeken JA. Aggressive biologic behavior of basal-and squamous-cell cancers in patients with chronic lymphocytic leukemia or chronic lymphocytic lymphoma. J Dermatol Surg Oncol 1979; 5: 609-14.
206. Gaugman LJ, Bergeron JR, Mullins JF. Giant basal cell epithelioma developing in acute burn site. Arch Dermatol 1969; 99: 594-5.
207. Burns DA, Calnan CD. Basal cell epithelioma in a chronic leg ulcer. Clin Exp Dermatol 1978; 3: 443-5.
208. Hendricks WM. Basal cell carcinoma arising in chickenpox scar. Arch Dermatol 1980; 116: 1304-5.
209. Rich JD, Shesol BF, Horne DW III. Basal cell carcinoma arising in a smallpox vaccination site. J Clin Pathol 1980; 33: 134-5.
210. Yeh S, How SW, Lin CS. Arsenical cancer of skin: histologic study with special reference to Bowen's disease. Cancer 1968; 21: 312-39.
211. Oettle AG. Rodent ulcers in identical twins. AMA Arch Dermatol 1956; 74: 167-72.
212. Fergin PE, Chu AD, MacDonald DM. Basal cell carcinoma complicating naevus sebaceus. Clin Exp Dermatol 1981; 6: 111-5.
213. Golberg HS. Basal cell epitheliomas developing in a localized linear epidermal naevus. Cutis 1980; 25: 295-7, 299.
214. Lillis PJ, Ceilley RI. Multiple tumors arising in naevus sebaceus. Cutis 1979; 23: 310-4.
215. Bale AE, Yu KP. The hedgehog pathway and basal cell carcinomas. Hum Mol Genet 2001; 10: 757-62.
216. Epstein E Jr. Genetic determinants of basal cell carcinoma risk. Med Oncol 2001; 36: 555-8.
217. Afzelius L-E, Ehnhage A, Nordgren H. Basal cell carcinoma in the head and neck. Acta Pathol Microbiol Scand 1980; 88A: 5-9.
218. Litzow TJ, Perry HO, Soderstrom CW. Morpheaform basal cell carcinoma. Am J Surg 1968; 116: 499-505.
219. Ridley CM, Spittle MF. Epitheliomas of the scalp after irradiation. Lancet 1974; i: 509 (Letter).
220. Gormley LJDE, Hirsch P. Aggressive basal cell carcinoma of the scalp. Arch Dermatol 1978; 114: 782-3.
221. Curry MC, Montgomery H, Winkelmann RK. Giant basal cell carcinoma. Arch Dermatol 1977; 113: 316-9.
222. Blewitt RW. Why does basal cell carcinoma metastasize so rarely? Int J Dermatol 1980; 19: 144-6.
223. Von Domarus H, Stevens PJ. Metastatic basal cell carcinoma: report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 1984; 10: 1043-60.
224. Farmer ER, Helwig EB. Metastatic basal cell carcinoma: a clinico-pathologic study of 17 cases. Cancer 1980; 46: 748-57.
225. Larson DL, Gillespie JJ, Parsons RW. Metastatic basal cell carcinoma of the lung. South Med J 1980; 73: 647-9.
226. Snow SN, Sahl W, Lo JS et al. Metastatic basal cell carcinoma. Cancer 1994; 73: 328-35.
227. Stell JS, Moyer DG, Dehne E. Basal cell epithelioma metastatic to bone. Arch Dermatol 1966; 93: 338-40.
228. Weedon D, Shand E. Amyloid in basal cell carcinomas. Br J Dermatol 1979; 101: 141-6.
229. Madsen A. Studies on basal-cell epithelioma of the skin: the architecture, manner of growth, and histogenesis of the tumours-whole tumours examined in serial sections cut parallel to the skin surface. Acta Pathol Microbiol Scand Suppl 1965; 117: 3-63.
230. Sanderson KV. The architecture of basal-cell carcinoma. Br J Dermatol 1961; 73: 455-74.
231. Van Scott EJ, Reinertson RP. The modulating influence of stromal environment on epithelial cells studied in human autotransplants. J Invest Dermatol 1961; 36: 109-17.
232. Weinstein GD, Frost P. Cell proliferation in human basal cell carcinoma. Cancer Res 1970; 30: 724-8.
233. Sherertz EF, Pollack SV, Jegasothy BV. Correlation of basal cell epithelioma aggressiveness with local inhibition of host lymphocyte response. Clin Res 1982; 30: 266 (Abstract).
234. Epstein E. How accurate is visual assessment of basal carcinoma margins? Br J Dermatol 1973; 89: 37-43.
235. Presser SE, Taylor JR. Clinical diagnostic accuracy of basal cell carcinoma. J Am Acad Dermatol 1987; 16: 988-90.
236. Fleming ID, Amonette R, Monaghan T, Fleming MD. Principles of management of basal and squamous cell carcinoma of the skin. Cancer 1995; 75 (Suppl. 2): 699-704.
237. Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35-48.
238. Smith SP, Grande DJ. Basal cell carcinoma recurring after radiotherapy: a unique, difficult treatment subclass of recurrent basal cell carcinoma. J Dermatol Surg Oncol 1991; 17: 26-30.
239. Spiller WF, Spiller RF. Treatment of basal cell epithelioma by curettage and electrodesiccation. J Am Acad Dermatol 1984; 11: 808-14.
240. Holt PJ. Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery. Br J Dermatol 1988; 119: 231-40.
241. Kuflik EG, Gage AA. The five-year cure rate achieved by cryosurgery for skin cancer. J Am Acad Dermatol 1991; 24: 1002.
242. Silverman MK, Kopf AW, Grin CM et al. Recurrence rates of treated basal cell carcinomas. II. Curettage-electrodesiccation. J Dermatol Surg Oncol 1991; 17: 720-6.
243. Zacarian SA. Cryosurgery of cutaneous carcinomas: an 18-year study of 3022 patients with 4228 carcinomas. J Am Acad Dermatol 1983; 9: 947-56.
244. Walker P, Hill D. Surgical treatment of basal cell carcinomas using standard post operative histological assessment. Australas J Dermatol 2006; 47: 1-12.
245. Marchac D, Papadopoulos O, Duport G. Curative and aesthetic results of surgical treatment of 138 basal cell carcinomas. J Dermatol Surg Oncol 1982; 8: 379-87.
246. Breuninger H, Dietz K. Prediction of subclinical tumor infiltration in basal cell carcinoma. J Dermatol Surg Oncol 1991; 17: 574-8.
247. Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol 1987; 123: 340-4.
248. Kimyai-Asadi A, Goldberg LH, Peterson SR et al. Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas. J Am Acad Dermatol 2005; 53: 464-8.
249. Johnson TM, Tromovitch TA, Swanson NA. Combined curettage and excision: a treatment method for primary basal cell carcinoma. J Am Acad Dermatol 1991; 24: 613-7.
250. Chiller K, Passaro D, McCalmont T, Vin-Christian K. Efficacy of curettage before excision in clearing surgical margins in non-melanoma skin cancer. Arch Dermatol 2000; 136: 1327-32.
251. Farley RL, Manolidis S, Ratner D. Aggressive basal cell carcinoma with invasion of the parotid gland, facial nerve and temporal bone. Dermatol Surg 2006; 32: 307-15.
252. Williams LS, Mancuso AA, Mendenhall WM. Perineural spread of cutaneous squamous and basal cell carcinoma. CT and MR detection and its impact on patient management and prognosis. Int J Radiat Oncol Biol Phys 2001; 49: 1061-9.
253. Sussman LA, Liggins DF. Incompletely excised basal cell carcinoma: a management dilemma? Aust NZ J Surg 1996; 66: 276-8.
254. Richmond JD, Davie RM. The significance of incomplete excision in patients with basal cell carcinoma. Br J Plast Surg 1987; 40: 63-7.
255. Park AJ, Strick M, Watson JD. Basal cell carcinomas: do they need to be followed up? J R Coll Surg Edinb 1994; 39: 109-11.
256. De Silva SP, Dellon AL. Recurrence rate of positive margin basal cell carcinoma: results of a five-year prospective study. J Surg Oncol 1985; 28: 72-4.
257. Wilson AW, Howsam G, Santhanam V et al. Surgical management of incompletely excised basal cell carcinomas of the head and neck. Br J Oral Maxillofac Surg 2004; 42: 311-4.
258. Leibovitch I, Huilgol SC, Selva D et al. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5 year follow up. J Am Acad Dermatol 2005; 53: 452-7.
259. Bianchini R, Wolter M. Fatal outcome in a metatypical, giant, 'horrifying' basal cell carcinoma. J Dermatol Surg Oncol 1987; 13: 556-7.
260. Farmer ER, Helwig EB. Metastatic basal cell carcinoma: a clinicopathologic study of 17 cases. Cancer 1980; 46: 748-57.
261. Smith JM, Irons GB. Metastatic basal cell carcinoma: review of the literature and report of three cases. Ann Plast Surg 1983; 11: 551-3.
262. Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol 2002; 138: 758-63.
263. Ramsay HM, Fryer AA, Hawley CM et al. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002; 147: 950-6.
264. Marks R, Staples M, Giles GG. Trends in non-melanocytic skin cancer treated in Australia: the second national survey. Int J Cancer 1993; 53: 585-90.
265. Chuang TY, Popescu NA, Su WDP et al. Squamous cell carcinoma: a population based incidence study in Rochester Minnesota. Arch Dermatol 1990; 126: 185-8.
266. Halder RM, Bridgeman-Shah S. Skin cancer in African Americans. Cancer 1995; 75 (Suppl. 2): 667-73.
267. Oettle AG. Skin Cancer in Africa. Monograph 10. Washington DC: National Cancer Institute, 1963: 197-214.
268. Okoro AN. Albinism in Nigeria. Br J Dermatol 1975; 92: 485-92.
269. Cross F. On a turf (peat) fire cancer: malignant change superimposed on erythema ab igne. Proc R Soc Med 1967; 60: 1307-8.
270. Peterkin GAG. Malignant change in erythema ab igne. BMJ 1955; ii: 1599-602.
271. Weschler HL, Krugh FJ, Domonkos A et al. Polydysplastic epidermolysis bullosa and development of epidermal neoplasms. Arch Dermatol 1970; 102: 374-80.
272. Oberste-Lehn H, Moll B. Porokeratosis Mibelli und Stachelzellcarcinom. Hautarzt 1968; 19: 399-403.
273. Hay DM, Cole FM. Postgranulomatous epidermoid carcinoma of the vulva. Am J Obstet Gynecol 1970; 108: 479-84.
274. Johnson RE, Ackerman LV. Epidermoid carcinoma of the hand. Cancer 1950; 3: 657-66.
275. Johnson WC, Helwig EB. Adenoid squamous cell carcinoma (adenoacanthoma): a clinicopathologic study of 155 patients. Cancer 1966; 19: 1639-50.
276. Lund HZ. Tumors of the skin. In: Atlas of Tumor Pathology, Section 1, Fasc. 2. Washington DC: Armed Forces Institute of Pathology, 1957: 235.
277. Stout AP. Gross pathology of cutaneous cancer. Arch Dermatol Syphilol 1946; 53: 597-8.
278. Willis RA, ed. Pathology of Tumours, 3rd edn. London: Butterworths, 1960.
279. Urbach F. Anatomy and Pathophysiology of Skin Tumor Capillaries. Monograph 10. Washington DC: National Cancer Institute, 1963: 539-59.
280. Dandy DJ, Munro DD. Squamous cell carcinoma of skin involving the median nerve. Br J Dermatol 1973; 89: 527-31.
281. Kwa RE, Campana K, Moy RL. Biology of cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992; 26: 1-26.
282. Swanbeck G, Hillström L. Analysis of etiological factors of squamous cell skin cancer or different locations. III. The arm and the hand. Acta Derm Venereol (Stockh) 1970; 50: 350-4.
283. Aird I, Johnson HD, Lennox B et al. Epithelioma cuniculatum: a variety of squamous carcinoma peculiar to the foot. Br J Surg 1954; 42: 245-50.
284. Driban NE, Lacognata JJ. Subungal squamous cell carcinoma. Dermatologica 1975; 150: 186-90.
285. Headington JT. Verrucous carcinoma. Cutis 1978; 21: 207-11.
286. Ackermann LV. Verrucous carcinoma of the oral cavity. Surgery 1948; 23: 670-9.
287. Davies SW. Giant condyloma acuminata: incidence among cases diagnosed as carcinoma of the penis. J Clin Pathol 1965; 18: 142-9.
288. South LM, O'Sullivan JP, Gazet JC. Giant condylomata of Buschke and Loewenstein. Clin Oncol 1977; 3: 107-15.
289. Foye G, Marshall MR, Minkowitz S. Verrucous carcinoma of the vulva. Obstet Gynaecol 1969; 34: 384-90.
290. Kao G, Graham JH, Helwig EB. Carcinoma cuniculatum. Cancer 1982; 49: 2395-403.
291. Graham JH, Helwig EB. Cutaneous Precancerous Conditions in Man. Monograph 10. Washington DC: National Cancer Institute, 1963: 323-3.
292. McGregor JM, Proby CM. Skin cancer in transplant recipients. Lancet 1995; 346: 964-5.
293. Hartevelt MM, Bavinck JN, Kootte AM et al. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990; 49: 506-9.
294. Boyle J, MacKie RM, Briggs JD et al. Cancer warts and sunshine in renal transplant patients. Lancet 1984; i: 702-5.
295. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: implications for treatment modality selection. J Am Acad Dermatol 1992; 26: 976-90.
296. Clayman GL, Lee JJ, Holsinger FC et al. Mortality risk from squamous cell skin cancer. J Clin Oncol 2005; 23: 759-65.
297. Moore BA, Weber RS, Prieto V et al. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope 2005; 115: 1561-7.
298. Veness MJ, Palme CE, Morgan GJ. High-risk cutaneous squamous cell carcinoma of the head and neck. Results from 266 treated patients with metastatic lymph node disease. Cancer 2006; 106: 2389-96.
299. Mullen JT, Feng L, Xing Y et al. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol 2006; 13: 902-9.
300. Dzubow LM, Rigel DS, Robins P. Risk factors for local recurrence of primary cutaneous squamous cell carcinomas. Arch Dermatol 1982; 118: 900-2.
301. Epstein E. Malignant sun-induced squamous cell carcinoma of the skin. J Dermatol Surg Oncol 1983; 9: 505-6.
302. Eroglu A, Berberoglu U, Berberoglu S. Risk factors related to locoregional recurrence in squamous cell carcinoma of the skin. J Surg Oncol 1996; 61: 124-30.
303. Friedman NR. Prognostic factors for local recurrence, metastases and survival rates in squamous cell carcinoma of the skin, ear and lip. J Am Acad Dermatol 1993; 28: 281-2.
304. Motley RJ, Preston PW, Lawrence CM. Multiprofessional Guidelines for the Management of the Patient with Primary Cutaneous Squamous Cell Carcinoma. www.bad. org.uk
305. Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992; 27: 241-8.
306. Veness MJ, Quinn DI, Ong CS et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer 1999; 85: 1758-64.
307. Barksdale SK, O'Connor N, Barnhill R. Prognostic factors for cutaneous squamous cell and basal cell carcinoma. Determinants of risk of recurrence, metastasis and development of subsequent skin cancers. Surg Oncol Clin N Am 1997; 6: 625-38.
308. Mendenhall WM, Parsons JT, Mendenhall NP et al. Carcinoma of the skin of the head and neck with perineural invasion. Head Neck 1989; 11: 301-8.
309. Cottel WI. Perineural invasion by squamous cell carcinoma. J Dermatol Surg Oncol 1982; 8: 589-600.
310. Friedman HI, Cooper PH, Wanebo HJ. Prognostic and therapeutic use of microstaging in cutaneous squamous cell carcinoma of the trunk and extremities. Cancer 1985: 56: 1099-105.
311. Breuninger H, Black B, Rassner G. Microstaging of squamous cell carcinomas. Am J Clin Pathol 1990: 94: 624-7.
312. Han A, Ratner D. What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion? Cancer 2007; 109: 1053-9.
313. Brewster AM, Lee JJ, Clayman GL et al. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol 2007; 25: 1974-8.
314. Kraemer KH, DiGiovanna JJ, Moshell AN et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1633-7.
315. Schnitzler L. [Retinoids and the prevention of cutaneous epitheliomas: 1977-87]. Ann Dermatol Vénéréol 1987; 114: 1537-43.
316. George R, Weightman W, Russ GR et al. Acitretin for chemoprevention of nonmelanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002; 43: 269-73.
317. Kovach BT, Sams HH, Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clin Transplant 2005; 19: 726-34.
318. Foulds L. Neoplastic Development, Vol. 1. New York: Academic Press, 1969.
319. Pinkus H, Jallad M, Mehregan AH. The inflammatory infiltrate of precancerous skin lesions. J Invest Dermatol 1963; 41: 247-8.
320. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol 2000; 115: 273-7.
321. Marks R, Foley P, Goodman G et al. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986; 115: 649-55.
322. Rehman I, Quinn AG, Healy E, Rees JL. High frequency of loss of heterozygosity in actinic keratoses, a usually benign disease. Lancet 1994; 344: 788-9.
323. Kushida Y, Miki H, Ohmori M. Loss of heterozygosity in actinic keratosis, squamous cell carcinoma and sun-exposed normal-appearing skin in Japanese: difference between Japanese and Caucasians. Cancer Lett 1999; 140: 169-75.
324. Marks R. Non-melanoma skin cancer and solar keratoses in Australia. Eur J Epidemiol 1985; 1: 319-22.
325. Marks R, Ponsford MW, Selwood TS et al. Non-melanotic skin cancer and solar keratoses in Victoria. Med J Aust 1983; 2: 619-22.
326. Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at subtropical latitude. Br J Dermatol 1998; 139: 1033-9.
327. Freeman RG. Carcinogenic effect of solar radiation and prevention measures. Cancer 1968; 21: 1114-20.
328. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000; 142: 1154-9.
329. Marks R, Foley P, Goodman G et al. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986; 115: 649-55.
330. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42: 4-7.
331. Pinkus H. Keratosis senilis: a biologic concept of its pathogenesis and diagnosis based on the study of normal epidermis and 1730 seborrhoeic and senile keratoses. Am J Clin Pathol 1958; 29: 193-207.
332. Shapiro L, Ackermann AB. Solitary lichen planus like actinic keratoses. Dermatologica 1966; 132: 386-92.
333. Civatte J, Schnitzler L, Belaïch S. Hyperplasie pseudo-épithéliomateuse du dos des mains. Ann Dermatol Syphiligr 1973; 100: 29-48.
334. Berhane T, Halliday GM, Cooke B, Barnetson RS. Inflammation is associated with progression of actinic keratoses to squamous cell carcinoma in humans. Br J Dermatol 2002; 146: 810-5.
335. de Berker D, McGregor JM, Hughes BR, on behalf of the British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses. Br J Dermatol 2007; 156: 222-30.
336. Szeimies RM, Karrer S, Radakovic-Fijan S et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47: 258-62.
337. Freeman M, Vinciullo C, Francis D et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. Dermatolog Treat 2003; 14: 99-106.
338. Goette DK. Topical chemotherapy with 5-fluorouracil: a review. J Am Acad Dermatol 1981; 4: 633-49.
339. Rivers JK, Arlette J, Shear N et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146: 94-100.
340. Wolf JE, Taylor JR, Tschen E, Kang S. Topical 3% diclofenac in 22.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-13.
341. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta analysis. J Dermatol 2006; 126: 1251-5.
342. Pearlman DL. Weekly pulse dosing: effective and comfortable 5-fluouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol 1991; 25: 665-7.
343. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluouracil cream and 5% fluouracil cream applied to each side of the face in patients with actinic keratoses. Clin Ther 2002; 24: 990-1000.
344. Kang S, Goldfarb MT, Weiss JB et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. J Am Acad Dermatol 2003; 49: 83-90.
345. Dijkstra AT, Majoie IM, van Dongen JW et al. Photodynamic therapy with violet light and topical 6-aminolaevulinic acid in the treatment of actinic keratosis, Bowen's disease and basal cell carcinoma. J Eur Acad Dermatol Venereol 2001; 15: 550-4.
346. Szeimies RM, Karrer S, Radakovic-Fijan S et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47: 258-62.
347. Morton CA, Campbell S, Gupta G et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 2006; 155: 1029-36.
348. Kaufmann R, Spelman L, Weightman W et al. Multicentre intra-individual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol 2008; 158: 994-9.
349. Coleman WP III, Yarborough JM, Mandy SH. Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol Surg 1996; 22: 17-21.
350. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993; 329: 1147-51.
351. Bowen JT. Precancerous dermatosis. J Cutan Dis 1912; 30: 241-55.
352. Bowen JT. Precancerous dermatosis: the further course of two cases previously reported. Arch Dermatol 1920; 1: 23-4.
353. Campbell C, Quinn AG, Ro YS et al. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J Invest Dermatol 1993; 100: 746.
354. Sau P, McMarlin SL, Sperling LC, Katz R. Bowen's disease of the nail bed and periungual area: a clinicopathologic analysis of seven cases. Arch Dermatol 1994; 130: 204-9.
355. Graham JH, Helwig EB. Bowen's disease and its relationship to systemic cancer. Arch Dermatol 1959; 80: 133-59.
356. Graham JH, Mazzanti GR, Helwig EB. Chemistry of Bowen's disease: relationship to arsenic. J Invest Dermatol 1961; 37: 317-32.
357. Tseng WP, Chu HM, How SW et al. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst 1968; 40: 453-63.
358. Callen JP, Headington J. Bowen's and non-Bowen's squamous intraepidermal neoplasia of the skin. Arch Dermatol 1980; 116: 422-6.
359. Sanderson KV. Multicentric pigmented Bowen's disease. Proc R Soc Med 1974; 67: 23-4.
360. Andersen SLC, Nielsen A, Reymann F. Relationship between Bowen's disease and internal malignant tumours. Arch Dermatol 1973; 108: 367-70.
361. Epstein E. Association of Bowen's disease with visceral cancer. Arch Dermatol 1960; 82: 349-51.
362. Kao GF. Carcinoma arising in Bowen's disease. Arch Dermatol 1986; 122: 1124-6.
363. Kao GF, Graham JH. Premalignant and malignant cutaneous disorders of the head and neck. In: English GM, Otolaryngology, Vol 5. New York: Harper & Row, 1986.
364. Peterka ES, Lynch FW, Goltz RW. An association between Bowen's disease and internal cancer. Arch Dermatol 1961; 84: 623-9.
365. Arbesmann H, Ranshoff DF. Is Bowen's disease a predictor for the development of internal malignancy? A methodological critique of the literature. JAMA 1987; 257: 516-8.
366. Chuang TY, Reizner GT. Bowen's disease and internal malignancy. J Am Acad Dermatol 1988; 19: 47-51.
367. Lycka BAS. Bowen's disease and internal malignancy: a meta-analysis. Int J Dermatol 1989; 28: 531-3.
368. Moller R, Nielsen A, Reymann F et al. Squamous cell carcinoma of the skin and internal malignant neoplasms. Arch Dermatol 1979; 115: 304-5.
369. Reymann F, Ravnborg L, Schon G et al. Bowen's disease and internal malignant disease. Arch Dermatol 1988; 124: 677-9.
370. Brownstein MH, Rabinowitz AD. The precursors of squamous cell carcinoma. Int J Dermatol 1979; 18: 1-16.
371. Ehlers G. Klinische und histologische Untersuchungen zur frage arzneimittelbedingter Arsen-Tumoren. Z Haut Geschlechts-Krankheiten 1968; 43: 763-74.
372. Seiji M, Mizuno F. Electron microscopic study of Bowen's disease. Arch Dermatol 1969; 99: 3-16.
373. Yeh S, Chen HC, How SW et al. Fine structure of Bowen's disease in chronic arsenicalism. J Natl Cancer Inst 1975; 53: 31-3.
374. Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen's disease. British Association of Dermatologists. Br J Dermatol 2007; 156: 11-21.
375. Holt PJ. Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery. Br J Dermatol 1988; 119: 231-40.
376. Cox NH, Dyson P. Wound healing on the lower leg after radiotherapy or cryotherapy of Bowen's disease and other malignant skin lesions. Br J Dermatol 1995; 133: 60-5.
377. Morton CA, Whitehurst C, Moseley H et al. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 1996; 135: 766-71.
378. Morton CA, Whitehurst C, McColl JH et al. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001; 137: 319-24.
379. Morton CA, Horn M, Leman J et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol 2006; 142: 729-35.
380. Patel GK, Goodwin R, Chawla M et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomised, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006; 54: 1025-32.
381. Montgomery H, Waisman M. Epithelioma attributable to arsenic. J Invest Dermatol 1941; 4: 365-83.
382. Rahman MM, Chowdury UK, Mukherjee SC et al. Chronic arsenic toxicity in Bangladesh and West Bengal: a review and commentary. J Toxicol Clin Toxicol 2001; 39: 683-700.
383. Hundeiker M, Petres J. Morphogenese und formenreichtum der arseninduzierten Präkanzerosen. Arch Klin Exp Dermatol 1968; 231: 355-65.
384. Yeh S, How SW, Lin CS. Arsenical cancer of skin: histologic study with special reference to Bowen's disease. Cancer 1968; 21: 312-39.
385. Centeno JA, Mullick FG, Martinez L et al. Pathology related to chronic arsenic exposure. Environ Health Perspect 2002; 110 (Suppl. 5): 883-6.
386. Yerebakan O, Ermis O, Yilmaz E, Basaran E. Treatment of arsenical keratoses and Bowen's disease with acetretin. Int J Dermatol 2002; 41: 84-7.
387. Chernosky ME, Anderson DE. Disseminated superficial actinic porokeratosis: genetic aspects. Arch Dermatol 1969; 99: 408-12.
388. Chernosky ME, Freeman RG. Disseminated superficial actinic porokeratosis (DSAP). Arch Dermatol 1967; 96: 611-24.
389. Donald GF, Hunter GA. Disseminated superficial actinic porokeratosis: a report of eight cases. Aust J Dermatol 1968; 9: 335-44.
390. Chernosky ME, Anderson DE. Disseminated superficial actinic porokeratosis. Arch Dermatol 1969; 99: 401-7.
391. Goerttler EA, Jung EG. Porokeratosis Mibelli and skin carcinoma: a critical review. Humangenetik 1975; 26: 291-6.
392. Shumack SP, Commens CA. Disseminated superficial actinic porokeratosis: a clinical study. J Am Acad Dermatol 1989; 20: 1015-8.
393. Xia K, Deng H, Xia HJ et al. A novel locus for disseminated superficial actinic porokeratosis maps to chromosome 15q25.1-26.1. Br J Dermatol 2002; 147: 650-4.
394. Reed RJ, Leone P. Porokeratosis: a mutant clonal keratosis of the epidermis. Arch Dermatol 1970; 101: 340-3.
395. Bondeson J. Everard Home, John Hunter and cutaneous horns: a historical review. Am J Dermatopathol 2001; 23: 362-9.
396. Queyrat L. Erythroplasie du gland. Bull Fr Soc Dermatol Syph 1911; 22: 378-82.
397. Goette DK. Erythroplasia of Queyrat. Arch Dermatol 1974; 110: 271-3.
398. Porter WM, Hawkins D, Dineen M, Bunker CB. Penile intraepithelial neoplasis: clinical spectrum and treatment of 35 cases. Br J Dermatol 2002; 147: 1159-65.
399. Wade TR, Kopf AW, Ackerman AB. Bowenoid papulosis of the genitalia. Arch Dermatol 1979; 115: 306-8.
400. Liu H, Urabe K, Moroi Y et al. Expression of p16 and hTERT protein is associated with the presence of high-risk human papillomavirus in Bowenoid papulosis. J Cutan Pathol 2006; 33: 551-8.
401. Emmerson RW. Multicentric pigmented Bowen's disease of the perineum. Proc R Soc Med 1975; 68: 345-6.
402. Lloyd KM. Multicentric pigmented Bowen's disease of the groin. Arch Dermatol 1970; 101: 48-51.
403. Berger BW, Hori Y. Multicentric Bowen's disease of the genitalia. Arch Dermatol 1978; 114: 1698-9.
404. Goorney BP, Polori R. A case of Bowenoid papulosis of the penis successfully treated with topical imiquimod cream 5%. Int J STD AIDS 2004; 15: 833-5.
405. Richter ON, Petrow W, Wardelmann E et al. Bowenoid papulosis of the vulva- immunotherapeutical approach with topical imiquimod. Arch Gynecol Obstet 2003; 268: 333-6.
406. McCallum DI, Kinmont PDC, Williams DW et al. Intra-epidermal carcinoma of the eyelid margin. Br J Dermatol 1975; 93: 239-52.
407. Kaugars GE, Pillion T, Svirsky JA et al. Actinic cheilitis: a review of 152 cases. Oral Med Oral Surg Oral Pathol 1999; 88: 181-6.
408. Wynder EL, Bross IJ. Aetiological factors in mouth cancer. BMJ 1957; i: 1137-43.
409. King GN, Healy CM, Glover MT et al. Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients. N Engl J Med 1995; 332: 1052-7.
410. Markopoulos A, Banidou-Farmaki E, Kayavis I. Actinic cheilitis: clinical and pathologic characteristics in 65 cases. Oral Dis 2004; 10: 212-6.
411. Stender IM, Wulf HC. Photodynamic therapy with 5-aminolevulinic acid in the treatment of actinic cheilitis. Br J Dermatol 1996; 135: 454-6.
412. Berking C, Herzinger T, Flaig MJ et al. The efficacy of photodynamic therapy in actinic cheilitis of the lower lip: a prospective study of 15 patients. Dermatol Surg 2007; 33: 825-30.
413. Fisher REW. Proceedings of the 13th International Congress on Occupational Health. 1961: 250.
414. Fisher REW. Trans Assoc Ind Med Off 1965; 15: 122.
415. Colomb D, Descos L, Gauthier D. Kérato-acanthomes multiples et maladie du brai de houille. Rev Lyonnaise Med 1966; 15: 449-62.
416. Letzel S, Drexler H. Occupationally related tumors in tar refinery workers. J Am Acad Dermatol 1998; 39: 712-20.
417. Yeatman JM, Kilkenny M, Marks R. The prevalence of seborrhoeic keratoses in an Australian population: does exposure to sunlight play a part in their frequency? Br J Dermatol 1997; 137: 411-4.
418. Memon AA, Tomenson JA, Bothwell J et al. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000; 142: 1154-9.
419. Williams MG. Acanthomata appearing after eczema. Br J Dermatol 1956; 68: 268-71.
420. Dantzig PI. Sign of Leser-Trélat. Arch Dermatol 1973; 108: 700-1.
421. Hafner C, van Oers JM, Vogt T et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest 2006; 116: 2201-7.
422. Logie A, Dunois-Larde C, Rosty C et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 2005; 14: 1153-60.
423. Hafner C, Lopez-Knowles E, Luis NM et al. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci USA 2007; 104: 13450-4.
424. Sanderson KV. The structure of seborrhoeic keratoses. Br J Dermatol 1968; 80: 588-93.
425. Mishima Y, Pinkus H. Benign mixed tumor of melanocytes and malpighian cells. AMA Arch Dermatol 1960; 81: 539-50.
426. Molokhia MM, Portnoy B. A study of dendritic cells in seborrhoeic warts. Br J Dermatol 1971; 85: 254-8.
427. Willoughby C, Soter NA. Stucco keratosis. Arch Dermatol 1972; 105: 859-61.
428. Kocsard E, Carter JJ. The papillomatous keratoses: the nature and differential diagnosis of stucco keratosis. Australas J Dermatol 1971; 12: 80-8.
429. Hairston MA Jr, Reed RJ, Derbes VJ. Dermatosis papulosa nigra. Arch Dermatol 1964; 89: 655-8.
430. Castellani A. Observations on some diseases of Central America. J Trop Med Hyg 1925; 28: 1-14.
431. Michael JC, Searle ER. Dermatosis papulosa nigra. Arch Dermatol Syphilol 1929; 20: 629-40.
432. Diasio FA. Dermatosis papulosa nigra (Castellani) of unusual distribution (acanthosis papulosa nigra). Arch Dermatol Syphilol 1933; 27: 751-5.
433. Sanderson KV, Wilson HTH. Haber's syndrome: familial rosacea-like eruption with intraepidermal epithelioma. Br J Dermatol 1965; 77: 1-8.
434. Seiji M, Otaki N. Haber's syndrome: familial rosacea-like dermatosis with keratotic plaques and pitted scars. Arch Dermatol 1971; 103: 452-5.
435. Degos R, Civatte J. Clear-cell acanthoma: experience of 8 years. Br J Dermatol 1970; 83: 248-54.
436. Wells GC, Wilson Jones E. Degos acanthoma (acanthoma à cellules claires): a report of five cases with particular reference to the histochemistry. Br J Dermatol 1967; 79: 249-58.
437. Zak FG, Girerd RJ. Das blasszellige Akanthom (Degos). Hautarzt 1968; 19: 559-61.
438. Duperrat B, Mascaro JM. L'acanthome a cellules unique: rapport de deux cas. Ann Dermatol Syphiligr 1965; 92: 5-6.
439. Fine RM, Chernosky ME. Clinical recognition of clear-cell acanthomas (Degos'). Arch Dermatol 1969; 100: 559-63.
440. Brownstein MH, Fernando S, Shapiro L. Clear cell acanthoma: clinicopathologic analysis of 37 new cases. Am J Clin Pathol 1973; 59: 306-11.
441. Funan H, Sisson JK. The ultrastructure of the pale cell acanthoma. J Invest Dermatol 1969; 52: 185-8.
442. Hollman KH, Civatte J. Etude au microscope électronique de l'acanthome à cellules claires. Ann Dermatol Syphiligr 1968; 95: 139-46.
443. Cramer HJ. Klarzellenakanthom (Degos) mit Syringomatösen und naevussebaceus-artigen Anteilen. Dermatologica 1971; 143: 265-70.
444. Rook A, Champion RH. Keratoacanthoma. Monograph 10. Washington DC: National Cancer Institute, 1963: 257-73.
445. Miyaji T. Skin Cancers in Japan: a Nationwide 5-Year Survey, 1956-60. Monograph 10. Washington DC: National Cancer Institute, 1963: 55-70.
446. Colomb D, Descos L, Gauthier D. Kératoacanthomes multiples et maladie du brac de houille. Rev Lyonaise Med 1966; 15: 449-62.
447. Ghadially FN, Barton BW, Kerridge DF. The etiology of keratoacanthoma. Cancer 1963; 16: 603-11.
448. Pillsbury DM, Beerman H. Multiple keratoacanthoma. Am J Med Sci 1958; 236: 614-24.
449. Wulsin JH. Keratoacanthoma: a benign cutaneous tumor arising in a skin graft. Am Surg 1958; 24: 689-92.
450. Dibden FA, Fowler M. The multiple growth of molluscum sebaceum in donor and recipient sites of skin graft. Aust NZ J Surg 1955; 25: 157-9.
451. Chapman RS, Finn OA. Carcinoma of the larynx in two patients with keratoacanthoma. Br J Dermatol 1974; 90: 685-8.
452. Poleksic S. Keratoacanthoma and multiple carcinomas. Br J Dermatol 1974; 91: 461-3.
453. Weber G, Stetter H, Pliess G. Assozilertes Vorkommen von eruptiven Keratoacanthomen, Tubercarcinom und Paramyeloblasten-leukamie. Arch Klin Exp Dermatol 1970; 238: 107-19.
454. Claudy A, Thivolet J. Multiple keratoacanthomas: association with deficient cell mediated immunity. Br J Dermatol 1975; 93: 593-5.
455. Bordea C, Wojnarowska F, Millard PR et al. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004; 77: 574-9.
456. Smith KJ, Haley H, Hamza S, Skelton HG. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg 2009, in press.
457. Kong HH, Cowen EW, Azad NS, Dahut W et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007; 56: 171-2.
458. Kingman J, Callen JP. Keratoacanthoma: a clinical study. Arch Dermatol 1984; 120: 736-40.
459. Calnan CD, Haber H. Molluscum sebaceum. J Pathol Bacteriol 1955; 69: 61-6.
460. Duany NP. Squamous cell pseudoepithelioma (keratoacanthoma): a new clinical variety, gigantic, multiple, and localized. AMA Arch Dermatol 1958; 78: 703-9.
461. Stevanovic DV. Keratoacanthoma: mucous membranes as the site of its localization. Dermatologica 1960; 121: 278-84.
462. Beare JM. Recurrent molluscum sebaceum. Lancet 1955; i: 182-3.
463. Lamp JC, Graham JH, Urbach F et al. Keratoacanthoma of the subungual region. J Bone Joint Surg Am 1964; 46: 1721-31.
464. Shapiro L, Baraf CS. Subungal epidermoid carcinoma and keratoacanthoma. Cancer 1970; 25: 141-52.
465. Kalkoff KW, Macher E. On the histogenesis of keratoacanthoma. Hautarzt 1961; 12: 8-15.
466. Burge KM, Winkelmann RK. Keratoacanthoma: association with basal and squamous cell carcinoma. Arch Dermatol 1969; 100: 306-11.
467. Ghadially FN. The role of the hair follicle in the origin and evolution of some cutaneous neoplasms of man and experimental animals. Cancer 1961; 14: 801-16.
468. Whiteley HJ. The effect of the hair growth cycle on experimental skin carcinogenesis in the rabbit. Br J Cancer 1957; 11: 196-205.
469. Zelickson AS. Virus-like particles demonstrated in keratoacanthomas by electron microscopy. Acta Derm Venereol (Stockh) 1962; 42: 23-6.
470. Grupper C. Treatment of keratoacanthomas by local applications of 5-fluorouracil (5-FU) ointment. Dermatologica 1970; 140 (Suppl. 1): 127-32.
471. Winkelmann RK, Brown J. Generalized eruptive keratoacanthoma: report of cases. Arch Dermatol 1968; 97: 615-23.
472. Winer LH. Pseudoepitheliomatous hyperplasia. Arch Dermatol Syphilol 1940; 42: 856-67.
473. Gillman T. The possible importance of dermal-epidermal interactions in the pathogenesis of human and experimental wound healing and skin cancers. In: Rook A, Champion RH, eds. Progress in the Biological Sciences in Relation to Dermatology. Cambridge: Cambridge University Press, 1964: 113.
474. Leppard BJ, Sanderson KV, Wells RS. Hereditary trichilemmal cysts: hereditary pilar cysts. Clin Exp Dermatol 1977; 2: 23-32.
475. Pinkus H. 'Sebaceous cysts' are trichilemmal cysts. Arch Dermatol 1969; 99: 544-55.
476. Leppard BJ, Bussey HJR. Gardner's syndrome with epidermoid cysts showing features of pilomatrixomas. Clin Exp Dermatol 1976; 1: 75-82.
477. McGauran MH, Binnington B. Keratinous cysts of the skin: identification and differentiation of pilar cysts from epidermal cysts. Arch Dermatol 1966; 94: 499-508.
478. Holmes EJ. Tumors of lower hair sheath: common histogenesis of certain socalled 'sebaceous cysts', acanthomas and 'sebaceous carcinomas'. Cancer 1968; 21: 234-48.
479. Leppard BJ, Sanderson KV. The natural history of trichilemmal cysts. Br J Dermatol 1976; 94: 379-90.
480. Wilson Jones E. Proliferating epidermoid cysts. Arch Dermatol 1966; 94: 11-9.
481. Mount LB. Steatocystome multiplex. Arch Dermatol Syphilol 1937; 36: 31-9.
482. Noojin RO, Reynolds JP. Familial steatocystome multiplex: twelve cases in three generations. Arch Dermatol Syphilol 1948; 57: 1013-8.
483. Sachs W. Steatocystome multiplex congenitale: ten cases in three generations. Arch Dermatol Syphilol 1938; 38: 877-80.
484. Amerlinck F. Sébocystomatose héréditaire. Arch Belges Dermatol Syphiligr 1949; 5: 187-91.
485. Schiff BL, Kern AB, Ronchese F. Steatocystoma multiplex. Arch Dermatol 1958; 77: 516-8.
486. Nicolaides N, Wells GC. On the biogenesis of the free fatty acids in human skin surface fat. J Invest Dermatol 1957; 29: 423.
487. Kligman AM, Kirschbaum JD. Steatocystoma multiplex: a dermoid tumor. J Invest Dermatol 1964; 42: 383-7.
488. Colomb D, Vittori F, Perraud R. Les épithéliomas baso-cellulaires et les tumeurs fibro-épithéliales de Pinkus multiples de la région lumbosacrée: discussion de role déclenchant d'un traitement radio-therapique antérieur-a propos de 4 observations. Semin Hop Paris 1975; 51: 2655-64.
489. Sarkany I, Fountain RB, Evans CD et al. Multiple basal-cell epitheliomata following radiotherapy of the spine. Br J Dermatol 1968; 80: 90-6.
490. Jaeger H, Delacrétaz J. Tumeurs fibro-épithéliales prémalignes de Pinkus: relation de deux nouveaux cas. Dermatologica 1956; 112: 364-70.
491. Degos R, Hewitt J. Tumeurs fibro-épithéliales prémalignes de Pinkus et épithélioma basocellulaire: a propos de deux cas nouveaux. Ann Dermatol Syphiligr 1995; 82: 124-39.